FDA approves First RSV vaccine for adults under 60

Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age. Tuesday’s label expansion covers younger adults who are deemed at higher risk of RSV-related lower respiratory tract disease.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
CDC Panel Backs Expanded Use Of Pfizer's Pneumococcal Vaccine
Pfizer Inc. (PFE) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo
Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 18-59 years who are at increased risk of the disease.
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker said.
FDA approves 1st RSV vaccine for adults under 60
The expansion builds on the previous indication for adults 60 years and older. The vaccine is also approved for pregnant individuals to protect infants from birth up to six months. With the decision,
Pfizer RSV vaccine Abrysvo gains expanded indication
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at increased risk of lower respiratory tract disease from the virus. Those conditions include obesity,
FiercePharma1d
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccines
With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...
McKnight's Long-Term Care News1d
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
As new COVID-19 strains emerge, how do vaccine manufacturers keep up with mutations of the virus?
New COVID-19 strains are emerging and with it the need for updated vaccines to protect people from the virus. So how do ...
The Washington Post10d
After Pfizer’s coronavirus vaccine success, CEO targeted for revenue slump
Barely three years ago, Pfizer was the toast of the pharmaceutical world and Bourla, who was elevated to the top job in 2019, wrote a book about the race to develop the coronavirus vaccine.
pharmaphorum3d
Pfizer plans considerable 2023 Comirnaty markup
Pfizer has now announced that ... and 100 times The People’s Vaccine Alliance’s estimated cost of manufacture of each vial. This estimation was drawn from an analysis of data from consumer ...
Reuters29d
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to ...